Lantheus’ PET Cardiac Imaging Studies To Be Highlighted At ASNC2010

Lantheus Medical Imaging, Inc., a global leading company providing medical imaging systems, announced that seven abstracts for studies discussing two of the company’s cardiac Positron Emission Tomography (PET) imaging agents are going to be highlighted at the 15th Annual Scientific Session of the American Society of Nuclear Cardiology (ASNC2010). The event will take place from the 23th to the 26th of September in Philadelphia. The abstracts are discussing the preliminary results of two curently conducted studies.

Lantheus To Provide DEFINITY In India

Lantheus Medical Imaging, Inc., a leading company offering diagnostic imaging solutions, announced that it has provided its DEFINITY® Vial, an ultrasound contrast imaging agent, in the market in India. Lantheus has closed a deal with J.B. Chemicals & Pharmaceuticals, Ltd. (JBCPL), a major company located in Mumbai,to distribute and market DEFINITY in India. DEFINITY, a Perflutren Lipid Microsphere ultrasound contrast agent, is already available in markets of Australia, New Zealand in addition to North America and several countries in the Middle East. In India, DEFINITY®  is indicated for patients with suboptimal echocardiograms, as it opacifys the left ventricle in addition to enhancing the delineation of the left ventricular endocardial border, it can also be sued in patients for contrast-enhanced diagnostic ultrasound imaging for better reviewing of focal lesions of the kidney and liver.

http://www.healthimaginghub.com/article/1592-lantheus-to-provide-definity-in-india.html